Taysha Gene Therapies, Inc. Common Stock (TSHA) Stock
NASDAQ · TSHA
5.02
Fundamentals
Market cap
$1.64B
Price / Earnings ratio
-11.2x
Price / Sales ratio
306.5x
Price / Book ratio
4.3x
Return on assets
-0.4%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.0%
Debt / Equity ratio
N/A
Latest news
About Taysha Gene Therapies, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees99
CEOMr. Sean P. Nolan
IPO DateSep 24, 2020
HeadquartersDallas, TX
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Sean P. Nolan | CEO & Chairman | 1968 |
| Dr. Sukumar Nagendran M.D. | President, Head of Research & Development and Director | 1967 |
| Mr. Kamran Alam CPA, M.B.A. | CFO & Corporate Secretary | 1978 |
| Hayleigh Collins | Director of Corporate Communications & Investor Relations | — |
| Mr. Michael B. Johannesen | Chief Legal Officer & Corporate Secretary | 1966 |
| Mr. Frederick Porter Ph.D. | Chief of Staff & Technical Operations Officer | — |
| Ms. Emily McGinnis M.P.H. | Chief Patient & External Affairs Officer | — |
| Mr. Sean McAuliffe | Chief Business Officer | — |
| Dr. Steven Gray Ph.D. | Chief Scientific Advisor of UT Southwestern Gene Therapy Program | — |
| Berge Minassian M.D. | Chief Medical Advisor of UT Southwestern Gene Therapy Program | — |
Fundamentals
Valuation
Market cap$1.64B
Price-to-sales ratio306.53
Price-to-book value4.34
Price-earnings ratio-11.20
Return on Equity-56.00%
Return on SalesN/A
Return on AssetsN/A
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.42
Income Statement
Average volume2,738,720
EBITDA$-127.36M
1 year high (52w)$7.30
1 year low (52w)$2.71
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A



